- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 23.07. | Jyong Biotech pursues global licensing partnerships for BPH drug | 3 | Investing.com | ||
| 23.07. | Jyong Biotech Ltd.: Jyong Biotech Highlights Multi-Billion Dollar Global BPH Market Opportunity and Reaffirms Strategic Focus on Global Licensing Partnerships | 218 | GlobeNewswire (Europe) | New Taipei City, Taiwan, July 23, 2026 (GLOBE NEWSWIRE) -- Jyong Biotech Ltd. (Nasdaq: MENS) (the "Company" or "Jyong Biotech"), a science-driven biotechnology company dedicated to the development... ► Artikel lesen | |
| JYONG BIOTECH Aktie jetzt für 0€ handeln | |||||
| 02.07. | Jyong Biotech presents drug candidate at BIO 2026 convention | 1 | Investing.com | ||
| 15.05. | Jyong Biotech Ltd. Files Annual Report on Form 20-F for Fiscal Year 2025 | 2 | GlobeNewswire (USA) | ||
| 15.05. | Jyong Biotech Ltd. - 20-F, Annual and transition report of foreign private issuers | - | SEC Filings | ||
| 28.04. | Jyong Biotech Ltd.: Jyong Biotech Updates Market Access Strategy for Innovative Botanical Drugs, Establishing Multiple Competitive Advantages for New Drug Portfolio | 4 | GlobeNewswire (USA) | ||
| 27.03. | Jyong Biotech Ltd.: Jyong Biotech Updates the Potential Clinical Benefits and Advantages of Its Plant-Derived Innovative Drug MCS-2 | 293 | GlobeNewswire (Europe) | New Taipei City, Taiwan, March 27, 2026 (GLOBE NEWSWIRE) -- Jyong Biotech Ltd. (Nasdaq: MENS) (the "Company" or "Jyong Biotech"), a science-driven biotechnology company dedicated to the development... ► Artikel lesen | |
| 12.02. | Jyong Biotech Ltd.: Jyong Biotech Reports Transformative Period of Clinical Validation and Commercialization Attempt: Phase II Data Focuses on Dual Therapeutic Potential of MCS-8 in Oncology and Metabolic Health, Alongside Strategic Market ... | 302 | GlobeNewswire (Europe) | - Comprehensive review of recent milestones highlights statistically significant efficacy in prostate cancer prevention, discovery of novel lipid-modulating properties, and the execution of high-value... ► Artikel lesen | |
| 06.02. | Jyong Biotech ernennt Wei (Vivi) Zhang zur neuen Finanzvorständin | 3 | Investing.com Deutsch | ||
| 06.02. | Jyong Biotech Ltd. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 30.01. | Jyong Biotech Ltd.: Jyong Biotech Subsidiary Announces Phase II Clinical Data on Cholesterol and LDH Indicators for MCS-8 (PCP), Indicating Potential in Prostate Cancer Prevention and Metabolic Value | 299 | GlobeNewswire (Europe) | New Taipei City, Taiwan, Jan. 30, 2026 (GLOBE NEWSWIRE) -- Jyong Biotech Ltd. (Nasdaq: MENS) (the "Company" or "Jyong Biotech"), a science-driven biotechnology company based in Taiwan committed to... ► Artikel lesen | |
| 19.12.25 | Jyong Biotech Ltd.: Jyong Biotech Responds to Share Price and Volume Movement | 517 | GlobeNewswire (Europe) | New Taipei City, Taiwan, Dec. 19, 2025 (GLOBE NEWSWIRE) -- Jyong Biotech Ltd. (Nasdaq: MENS) (the "Company" or "Jyong Biotech") notes the recent fluctuation in its share price and the increased trading... ► Artikel lesen | |
| 04.12.25 | Jyong Biotech Ltd.: Jyong Biotech Expands Regional Partnerships, Signs MOU with a Vietnam Pharmaceutical Distributor for MCS-2 Market Entry | 339 | GlobeNewswire (Europe) | New Taipei City, Taiwan, Dec. 04, 2025 (GLOBE NEWSWIRE) -- Jyong Biotech Ltd. (Nasdaq: MENS) (the "Company" or "Jyong Biotech"), a science-driven biotechnology company based in Taiwan committed to... ► Artikel lesen | |
| 24.11.25 | Jyong Biotech Ltd. Signs Non-Binding Letter of Intent with Leading South Korean Pharmaceutical Company to Evaluate In-Licensing of Plant-Derived MCS Drugs | 476 | GlobeNewswire (Europe) | New Taipei City, Taiwan, Nov. 24, 2025 (GLOBE NEWSWIRE) -- Jyong Biotech Ltd. (Nasdaq: MENS) (the "Company" or "Jyong Biotech"), a science-driven biotechnology company based in Taiwan committed to... ► Artikel lesen | |
| 20.11.25 | Jyong Biotech Ltd.: Jyong Biotech Announces Completion of Primary Endpoint Statistical Analysis for Phase II Clinical Trial of MCS-8 With Positive Outcomes | 394 | GlobeNewswire (Europe) | New Taipei City, Taiwan, Nov. 20, 2025 (GLOBE NEWSWIRE) -- Jyong Biotech Ltd. (Nasdaq: MENS) (the "Company" or "Jyong Biotech"), a science-driven biotechnology company based in Taiwan committed to... ► Artikel lesen | |
| 16.09.25 | Jyong Biotech Ltd.: Jyong Biotech Announces Completion of Patient Enrollment of over 700 subjects in Phase II Clinical Trial of MCS-8 for Prostate Cancer Prevention | 592 | GlobeNewswire (Europe) | New Taipei City, Taiwan, Sept. 16, 2025 (GLOBE NEWSWIRE) -- Jyong Biotech Ltd. (Nasdaq: MENS) (the "Company", "Jyong Biotech"), a science-driven biotechnology company based in Taiwan committed to... ► Artikel lesen |
16 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| INOVIO PHARMACEUTICALS | 0,595 | +4,12 % | Inovio Pharmaceuticals, Inc.: INOVIO Announces Pricing of $20.0 Million Public Offering | PLYMOUTH MEETING, Pa., July 29, 2026 /PRNewswire/ -- INOVIO Pharmaceuticals, Inc. (Nasdaq: INO), a biotechnology company focused on developing and commercializing... ► Artikel lesen | |
| INFLARX | 1,489 | +0,68 % | InflaRx NV im Blickpunkt: Die Entwicklung die jetzt niemand auf dem Schirm hat - Meine klare Einschätzung dazu | ||
| INTELLIA THERAPEUTICS | 9,300 | -3,43 % | Intellia Therapeutics, Inc.: Intellia Therapeutics Reports Additional Positive Phase 3 Results for Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema | Data from HAELO Phase 3 clinical trial presented today in a late-breaking oral session at European Academy of Allergy & Clinical Immunology Annual Congress 2026HAELO manuscript simultaneously published... ► Artikel lesen | |
| IBIO | 1,172 | -3,86 % | iBio, Inc.: iBio Reports Single Dose of IBIO-610 Achieved Near-Complete Active Activin E Inhibition Through Eight Weeks in Obese NHP Study | Single-dose IBIO-610 achieved up to 98% inhibition of active Activin E through eight weeks, supporting a differentiated, long-acting antibody approach When combined with semaglutide, IBIO-610 drove... ► Artikel lesen | |
| IMMUNITYBIO | 6,220 | -3,86 % | ImmunityBio, Inc. - 8-K, Current Report | ||
| IMMATICS | 7,900 | 0,00 % | Immatics Announces Upcoming Presentations Across Its PRAME Franchise at ESMO Congress 2026 | Houston, Texas and Tuebingen, Germany, July 17, 2026 - Immatics N.V. (NASDAQ: IMTX, "Immatics" or the "Company"), the global leader in precision targeting of PRAME with multiple clinical-stage programs... ► Artikel lesen | |
| MANNKIND | 3,377 | -4,90 % | MannKind Reports Positive Phase 1b INFLO-1 Results, Demonstrating Safety and Tolerability of Nintedanib DPI and Clinical Validation of Its DPI Technology in IPF | Generally well-tolerated with no serious adverse events, bronchospasm or diarrhea; no study drug discontinuations 90% of patients had no [60%] or mild [30%] cough~450 total inhalations administered... ► Artikel lesen | |
| IMMUNIC | 12,465 | +2,42 % | EQS-News: Immunic AG: Immunic to Participate in Investor Conferences in July | Issuer: Immunic AG
/ Key word(s): Conference
Immunic to Participate in Investor Conferences in July
09.07.2026 / 12:30 CET/CEST
The issuer is solely responsible for... ► Artikel lesen | |
| IOVANCE BIOTHERAPEUTICS | 3,590 | -11,90 % | Iovance Biotherapeutics, Inc.: Iovance Biotherapeutics to Report Second Quarter 2026 Financial Results and Corporate Updates on Thursday, August 6, 2026 | ||
| MOLECULIN BIOTECH | 0,395 | 0,00 % | Moleculin Biotech, Inc.: Moleculin Announces Pricing of $9.3 Million Public Offering | HOUSTON, July 31, 2026 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), today announced the pricing of a best-efforts public offering of an aggregate of... ► Artikel lesen | |
| GENPREX | 5,820 | -18,26 % | Genprex, Inc. - 8-K, Current Report | ||
| MACROGENICS | 3,160 | -4,24 % | Citizens reiterates MacroGenics stock rating ahead of ESMO data | ||
| MESOBLAST | 1,302 | +3,25 % | Novo Nordisk revolutionierte Diabetes, CAR-T die Krebsmedizin - könnte Mesoblast die nächste Biotech-Plattform aufbauen? | ||
| KARYOPHARM | 1,660 | -72,79 % | Karyopharm Therapeutics Inc.: Karyopharm Announces Topline Results from Phase 3 XPORT-EC-042 Trial in Endometrial Cancer | - The Trial Did Not Meet the Primary Endpoint of Progression-Free Survival (PFS) -
- A Trend Favoring the Selinexor Arm was Observed with a 5.3 Month Improvement... ► Artikel lesen | |
| MEREO BIOPHARMA | 0,288 | +4,35 % | Mereo BioPharma Group plc: Mereo BioPharma Reports First Quarter 2026 Financial Results and Provides Corporate Updates | LONDON, May 12, 2026 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) ("Mereo" or the "Company"), a clinical-stage biopharmaceutical company focused on rare diseases, today announced financial... ► Artikel lesen |
Das Unternehmen JYONG BIOTECH LTD kann der Branche Biotechnologie zugeordnet werden. Der aktuelle Kurs liegt bei 2,150 Euro und damit -3,59 % im Minus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu JYONG BIOTECH LTD finden Sie auf Wallstreet Online.